322055 VO Innovation and Leadership - M14 (2017S)
Labels
Vorlesungstermine:
22.03.+23.03.2017 18.00-19.30 Uhr
29.03.+30.03.2017 18.00-20.00 Uhr
05.04.+06.04.2017 18.00-20.00 Uhr
10.05.+11.05.+17.05.+18.05.2017 18.00-20.00 Uhr
Seminarraum 2D313
22.03.+23.03.2017 18.00-19.30 Uhr
29.03.+30.03.2017 18.00-20.00 Uhr
05.04.+06.04.2017 18.00-20.00 Uhr
10.05.+11.05.+17.05.+18.05.2017 18.00-20.00 Uhr
Seminarraum 2D313
Details
Sprache: Englisch
Prüfungstermine
Lehrende
Termine (iCal) - nächster Termin ist mit N markiert
- Mittwoch 22.03. 18:00 - 19:30 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Donnerstag 23.03. 18:00 - 19:30 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Mittwoch 29.03. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Donnerstag 30.03. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Mittwoch 05.04. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Donnerstag 06.04. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Mittwoch 10.05. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Donnerstag 11.05. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Mittwoch 17.05. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
- Donnerstag 18.05. 18:00 - 20:00 Seminarraum Arzneistoffsynthese 2D313 3.OG UZA II
Information
Ziele, Inhalte und Methode der Lehrveranstaltung
The pharmaceutical industry has produced impressive breakthrough medicines such as, insulin, first in class vaccines, antibiotics, retroviral and cancer therapies that have significantly impacted our society. Furthermore, rapid advances in technology, and infrastructure have resulted due to advancing R & D needs throughout the evolving process of designing new therapies. However, the industry has been criticized during the last decade for its lack of innovation. What exactly does ‘lack of innovation’ mean? Clearly the need to ‘be innovative’ is obvious. However, the process of finding novel solutions to problems, recognizing good ideas that meet needs and produce disruptive technologies or services to the market is extremely challenging.
Art der Leistungskontrolle und erlaubte Hilfsmittel
Mindestanforderungen und Beurteilungsmaßstab
This course will introduce the concept of innovation and disruptive technology as well as review exemplary innovators in health care and other industries. Armed with this knowledge, students will interactively experience the process of innovation in the context of a project related to pharmaceutical science that will provide a framework to explore the unique leadership competencies required to guide and shape creative teams and inspire the imagination needed to recognize a good idea and transform it into a useful or even disruptive technology. This course is in English and fulfills 1 ECTS.
Prüfungsstoff
Literatur
Zuordnung im Vorlesungsverzeichnis
MA23, A400
Letzte Änderung: Sa 02.04.2022 00:27